Nina Williams, MD
Advanced Heart Failure and Transplant Cardiology · Tulsa, OKNPI 1518370337
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 199 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Abbott at 26.0% of the total.
Across 199 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Novartis$605
- Abiomed$502
- Boston Scientific$233
- Johnson & Johnson$204
- Amgen$179
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,40596%
- Education$1954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 40 | $1,196 |
| Novartis | 28 | $605 |
| Abiomed | 7 | $502 |
| Boston Scientific | 10 | $233 |
| Johnson & Johnson | 7 | $204 |
| Amgen | 11 | $179 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $160 |
| E.r. Squibb & Sons, L.L.C. | 8 | $131 |
| Novo Nordisk | 7 | $126 |
| Pfizer | 8 | $125 |
| Merck | 8 | $119 |
| Alnylam Pharmaceuticals Inc. | 6 | $112 |
| AstraZeneca | 5 | $99 |
| Bayer | 4 | $78 |
| Boehringer Ingelheim | 5 | $74 |
| Lexicon Pharmaceuticals, Inc. | 4 | $73 |
| Cardinal Health 200 LLC | 1 | $65 |
| Sanofi-aventis U.S. LLC | 3 | $65 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Akcea Therapeutics, Inc. | 2 | $50 |
| Actelion Pharmaceuticals US, Inc. | 3 | $45 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $42 |
| Angiodynamics, Inc. | 2 | $39 |
| Philips North America LLC | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Impulse Dynamics (USA) Inc. | 2 | $29 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Nuwellis, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$368
- HeartMate 3 Left Ventricular Dev$195
- XARELTO$115
- Xience Sierra CSS$114
How this compares
Too few advanced heart failure and transplant cardiology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 353 | $358,421 |
| EntrestoSacubitril/Valsartan | 147 | $137,205 |
| JardianceEmpagliflozin | 97 | $96,469 |
| XareltoRivaroxaban | 58 | $64,075 |
| Repatha SureclickEvolocumab | 32 | $20,639 |
| FarxigaDapagliflozin Propanediol | 11 | $14,072 |
| Praluent PenAlirocumab | 19 | $10,078 |
| Metoprolol Succinate | 362 | $6,378 |
| BrilintaTicagrelor | 14 | $5,958 |
| Atorvastatin Calcium | 192 | $4,801 |
| Rosuvastatin Calcium | 124 | $4,057 |
| Diltiazem 12hr ErDiltiazem Hcl | 13 | $4,032 |
| Potassium Chloride | 206 | $3,449 |
| Losartan Potassium | 216 | $2,576 |
| Carvedilol | 173 | $1,689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $125 | $358,421353 claims |
| NovartisEntresto | $605 | $137,205147 claims |
| Boehringer IngelheimJardiance | $74 | $96,46997 claims |
| Johnson & JohnsonXarelto | $204 | $64,07558 claims |
| AstraZenecaFarxiga, Brilinta | $99 | $20,03025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Tulsa
- Steven StroudTulsa$39K
- Luis Meggo QuirozTulsa$19K
- Ralph EnsleyTulsa$11K
- John VannTulsa$9K
- Luke CunninghamOklahoma City$70K
- Tarun DasariOklahoma City$2K
- Carol KepfordOklahoma City$716
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.